This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES: Oligonucleotide & Peptide Therapeutics Content Hub
24/7 Access
Digital & In-Person
Menu

Anil Kore
Director, Chemistry & Biology at Thermo Fisher Scientific
Speaker

Profile

In 1996, Dr. Kore received his Ph.D. in Bioorganic Chemistry from Shivaji University, Kolhapur (India), where he worked on synthesis and hybridization of fluorescent labeled Oligonucleotide probes and their therapeutic applications. From 1997 to 2000, his post-doctoral research on the synthesis of modified nucleosides/nucleotides and selection of unnatural hammerhead like ribozymes was carried out at Max-Planck Institute for Experimental Medicine , Gottingen (Germany) with Professor Fritz Eckstein. Last 19 plus years, the main focus of his research at Thermo Fisher Scientific has been on the discovery, development and manufacture of oligonucleotide based therapeutics, DNA and RNA amidites/modifications in combinatorial and diagnostic research. A new design, synthesis and screening of novel dinucleotide cap analogues for 5’ capped mRNA, and modified peptides as a proteinase K inhibitor and Lipid Chemistry to develop as a transfecting reagents for delivery purpose.

Dr. Kore have authored over 83 scientific publications in leading journals, and have inventorship of more than 11 patents. Throughout his professional history, he has attended and made numerous presentations at local and international scientific meetings and acted as a chair for symposium session. He also serves as an Associate Editor, Current Protocols in Nucleic Acid Chemistry (CPNC), Wiley. He is also recipient of 2013 Presidential Green Chemistry Challenge Award given by the Environmental Protection Agency (EPA) for Greener Synthetic Pathways for manufacturing of various dNTPs for RT/PCR.

Agenda Sessions

  • Advancing and Enabling Commercial-Scale Manufacturing of Nucleic Acid Based Medicine

    On Demand - For Members